Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M. Cona MS, et al. Among authors: necchi a. Cancers (Basel). 2019 Feb 14;11(2):223. doi: 10.3390/cancers11020223. Cancers (Basel). 2019. PMID: 30769874 Free PMC article.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Necchi A, et al. Lancet Oncol. 2012 Aug;13(8):810-6. doi: 10.1016/S1470-2045(12)70294-2. Epub 2012 Jul 20. Lancet Oncol. 2012. PMID: 22819172 Clinical Trial.
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.
Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Giannatempo P, et al. Among authors: necchi a. J Urol. 2013 Nov;190(5):1919-24. doi: 10.1016/j.juro.2013.04.057. Epub 2013 Apr 25. J Urol. 2013. PMID: 23624209
Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases.
Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Necchi A, Giannatempo P, Raggi D, Fare' E, Colecchia M, Pizzocaro G, Salvioni R, Nicolai N. Lughezzani G, et al. Among authors: necchi a. BJU Int. 2015 Nov;116(5):727-33. doi: 10.1111/bju.12510. Epub 2015 Jul 6. BJU Int. 2015. PMID: 24128128
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R. Necchi A, et al. Clin Genitourin Cancer. 2014 Feb;12(1):63-69.e1. doi: 10.1016/j.clgc.2013.07.005. Epub 2013 Oct 23. Clin Genitourin Cancer. 2014. PMID: 24161525 Clinical Trial.
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Necchi A, et al. Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719. Epub 2013 Nov 14. Br J Cancer. 2014. PMID: 24231947 Free PMC article. Clinical Trial.
The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience.
Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Crestani A, Guttilla A, Raggi D, Giannatempo P, Necchi A, Pizzocaro G, Colecchia M, Salvioni R, Nicolai N. Lughezzani G, et al. Among authors: necchi a. J Urol. 2014 Apr;191(4):977-82. doi: 10.1016/j.juro.2013.10.140. Epub 2013 Nov 18. J Urol. 2014. PMID: 24262497
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Necchi A, Miceli R, Pedrazzoli P, Giannatempo P, Secondino S, Di Nicola M, Farè E, Raggi D, Magni M, Matteucci P, Longoni P, Milanesi M, Paternò E, Ravagnani F, Arienti F, Nicolai N, Salvioni R, Carlo-Stella C, Gianni AM. Necchi A, et al. Clin Genitourin Cancer. 2014 Jun;12(3):196-202.e1. doi: 10.1016/j.clgc.2013.11.021. Epub 2013 Nov 13. Clin Genitourin Cancer. 2014. PMID: 24361054
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R. Necchi A, et al. Clin Genitourin Cancer. 2014 Jun;12(3):203-209.e1. doi: 10.1016/j.clgc.2013.11.022. Epub 2013 Nov 21. Clin Genitourin Cancer. 2014. PMID: 24394493
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F. Necchi A, et al. Invest New Drugs. 2014 Jun;32(3):555-60. doi: 10.1007/s10637-014-0074-9. Epub 2014 Feb 26. Invest New Drugs. 2014. PMID: 24566706 Clinical Trial.
432 results